Efficacy, effectiveness and side effects of medications used to prevent fractures. (Q41704607)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Efficacy, effectiveness and side effects of medications used to prevent fractures (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

I R Reid

series ordinal

1

1 reference

7 October 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

690-706

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Calcium supplementation of the diet--II

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial--the OSTPRE-FPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

An International Comparison of Serum 25-Hydroxyvitamin D Measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Influence of calcium intake and physical activity on proximal femur bone mass and structure among pre- and postmenopausal women. A 10-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Risk factors for increased bone loss in an elderly population: the Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Factors affecting bone loss around menopause in women without HRT: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Calcium/vitamin D supplementation and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Vitamin D receptor in osteoblasts is a negative regulator of bone mass control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

A pooled analysis of vitamin D dose requirements for fracture prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Prediction of vitamin D deficiency by simple patient characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Fracture risk remains reduced one year after discontinuation of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Characterization of and risk factors for the acute-phase response after zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The incidence of acute anterior uveitis after intravenous zoledronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Esophageal and gastric cancer incidence and mortality in alendronate users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Fragility fractures of the hip and femur: incidence and patient characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Incidence of atypical nontraumatic diaphyseal fractures of the femur

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

Evidence that increased calcium intake does not prevent early postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12339

21 January 2018

Identifiers

DOI

10.1111/JOIM.12339

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495429%20AND%20SRC:MED&resulttype=core&format=json

release_3ngipbsdxngkjeycwc5u4mpyey

24 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3ngipbsdxngkjeycwc5u4mpyey

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference